The Art of
Licensing 		The Art of
Development 		The Art of
Access 		The Art of
Manufacturing 		The Art of
Partnership
Home > The Art of Licensing > About Helsinn > News > 2009
2009
16.12.2009HELSINN BIREX PHARMACEUTICALS WINS RESPONSIBLE CARE AWARD FOR WASTE MANAGEMENT
29.09.2009HELSINN: 25 YEARS IN BIASCA
22.10.2009PALONOSETRON EFFECTIVELY PREVENTS EMESIS AND NAUSEA INDUCED BY HIGH DOSE CHEMOTHERAPY IN PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION
17.09.2009HELSINN WILL PRESENT AT THE UBS GLOBAL LIFE SCIENCES CONFERENCE IN NEW YORK, USA, SEPTEMBER 22ND 2009
15.09.2009HELSINN PARTNERS WITH EISAI FOR GELCLAIR IN ITALY
10.09.2009TAIWAN MEETS ALOXI: LAUNCH EVENT HEADED BY PROF. STEVEN GRUNBERG
09.09.2009NEW CHIEF EXECUTIVE OFFICER AND VICE PRESIDENT COMMERCIAL OPERATIONS USA AT THE HELSINN GROUP’S AMERICAN SUBSIDIARY, HELSINN THERAPEUTICS (U.S.) INC.
07.09.2009HELSINN WILL PRESENT AT THE RODMAN & RENSHAW 11TH ANNUAL HEALTHCARE CONFERENCE IN NEW YORK, USA, SEPTEMBER 9TH 2009
30.06.2009SUPPORTIVE CARE IN CANCER: PALONOSETRON RECOMMENDED 5-HT3 ANTAGONIST FOR EMESIS PREVENTION BY MASCC/ESMO
25.06.2009SECOND GENERATION 5-HT3 ANTAGONISTS OPEN NEW PERSPECTIVES IN EMESIS PREVENTION
22.06.2009HELSINN ANNOUNCES NEW PLANS FOR ITS MANUFACTURING OPERATIONS
15.06.2009MORE THAN POSITIVE OUTCOME FOR HELSINN’S PARTICIPATION IN THE 2009 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING
05.06.2009SINGLE DOSE PALONOSETRON PREVENTS EMESIS INDUCED BY CHEMOTHERAPY IN NON HODGKIN’S LYMPHOMA PATIENTS
03.06.2009HELSINN’S PLANTS IN BIASCA ISO 14001 AND OHSAS 18001 CERTIFIED
02.04.2009HELSINN AND TÁNAISTE ANNOUNCE NEW R&D CENTRE-OF-EXCELLENCE AT HELSINN IN DUBLIN
02.04.2009PALONOSETRON “PREFERRED” 5-HT3 ANTAGONIST FOR EMESIS PREVENTION IN ONCOLOGY PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY
20.03.2009PALONOSETRON WARRANTS ADEQUATE CALORIC INTAKE IN ONCOLOGY PATIENTS RECEIVING HIGH EMETOGENIC CHEMOTHERAPY
03.03.2009HELSINN GRANT TO THE INSTITUTE OF RESEARCH IN BIOMEDICINE, BELLINZONA, SWITZERLAND
25.02.2009THE POSITIVE OUTCOME OF HELSINN CHEMICAL OPERATION'S PARTICIPATION IN INFOMEX USA 2009
28.01.2009HELSINN ANNOUNCES THE ACQUISITION OF SAPPHIRE THERAPEUTICS INC., USA TO ESTABLISH HELSINN THERAPEUTICS (US) INC.
26.01.2009HELSINN’S GRANT TO SUPPORT EURORDIS ACTIVITIES
14.01.2009IS PALONOSETRON TO BECOME STANDARD TREATMENT FOR PREVENTING CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV)?
 
Home
Legal Statement
News
Contacts
Sitemap
Document Central
Jobs
Helsinn′s Board of Directors and Top Management
Links
Printer Friendly
Copyright © Helsinn Group - Legal Statement
Last Update: 22.05.2013
Free acces to Helsinn newsletter
Subscribe  or Unsubscribe
About Helsinn Our Products Our Partners